CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-28 | WIERENGA WENDALL Director | Option exercise 10b5-1 | +4,452 | $7.37 | $33K | 29,011 |
| 2024-10-28 | WIERENGA WENDALL Director | Sale 10b5-1 | −4,452 | $52.25 | $233K | 24,559 |
| 2024-10-28 | WIERENGA WENDALL Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −4,452 | 1,484 | ||
| 2024-10-15 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +5,300 | $7.96 | $42K | 124,220 |
| 2024-10-15 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −5,300 | $54.18 | $287K | 118,920 |
| 2024-10-15 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $54.20 | $108K | 116,920 |
| 2024-10-15 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,300 | 21,200 | ||
| 2024-10-09 | Blum Robert I President & CEO | Option exercise 10b5-1 | +5,000 | $6.67 | $33K | 402,456 |
| 2024-10-09 | Blum Robert I President & CEO | Sale 10b5-1 | −5,000 | $55.61 | $278K | 397,456 |
| 2024-10-09 | Blum Robert I President & CEO | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,000 | 69,727 | ||
| 2024-10-01 | Harrington Robert Arthur Director | Grant or award | +237 | $52.60 | $12K | 15,753 |
| 2024-10-01 | HENDERSON JOHN T Director | Grant or award | +403 | $52.60 | $21K | 38,461 |
| 2024-10-01 | Kaye Edward M. MD Director | Grant or award | +237 | $52.60 | $12K | 25,382 |
| 2024-10-01 | WIERENGA WENDALL Director | Grant or award | +118 | $52.60 | $6K | 24,559 |
| 2024-10-01 | Wysenski Nancy Director | Grant or award | +118 | $52.60 | $6K | 22,988 |
| 2024-10-01 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $52.11 | $104K | 118,920 |
| 2024-10-01 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +5,300 | $7.96 | $42K | 124,220 |
| 2024-10-01 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −5,300 | $52.09 | $276K | 118,920 |
| 2024-10-01 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,300 | 26,500 | ||
| 2024-09-30 | Blum Robert I President & CEO | Option exercise 10b5-1 | +5,000 | $6.67 | $33K | 402,456 |
Page 27 of 33 · 660 trades